Machine learning-based prediction of one-year mortality after alloHCT identifies the impact of pre-transplant immunity and inflammation
Accurate prediction of mortality after allogeneic hematopoietic stem cell transplantation (alloHCT) is essential for individualized treatment decisions, yet existing clinical risk scores capture only a limited number of variables and show modest predictive performance. In our single-center retrospective analysis, we included data from 909 adult patients with hematologic malignancies undergoing alloHCT. We used 31 features to build machine-learning models to predict death within the first year after alloHCT. These features included established clinical risk factors together with pre-transplant lymphocyte subsets and inflammatory markers. Among four models, a random forest algorithm showed the best performance (AUC = 0.773) and retained good generalizability in an independent test set (AUC = 0.748). SHapley Additive exPlanations (SHAP)-based interpretation of the machine-learning models showed that age together with five easily measurable pre-transplant immunological and inflammatory parameters influenced the outcome: pre-transplant CD4<sup>+</sup>, CD8<sup>+</sup>, and B-lymphocyte counts, albumin, and C-reactive protein (CRP) levels. Based on these features, our random forest approach outperformed established clinical risk scores (HCT-CI, EASIX, rDRI, mGPS) in predicting one-year mortality after alloHCT and more effectively distinguished patients at low and high risk of an adverse outcome. Our study shows that machine-learning-based models can not only predict patient outcomes after alloHCT but also serve as powerful tools for data exploration, confirming the prognostic relevance of pre-transplant inflammation while uncovering the critical role of lymphocyte subsets as previously unknown risk factors. External validation in independent multicenter cohorts will be required to confirm generalizability.
Authors
- Laura Gengenbach
- Jesús Duque‐Afonso (ORCID: https://orcid.org/0000-0002-8287-5673)
- Thomas Meyer (ORCID: https://orcid.org/0000-0001-7228-5365)
- J Finke
- Christoph Rummelt (ORCID: https://orcid.org/0000-0002-6471-7030)
- Daniela Oelke
- Hartmut Bertz (ORCID: https://orcid.org/0000-0002-3805-8123)
- Claudia Wehr (ORCID: https://orcid.org/0000-0002-5037-6175)
- Ralph Wäsch (ORCID: https://orcid.org/0000-0002-0813-3444)
- Robert Meyer (ORCID: https://orcid.org/0000-0002-5693-2216)
- Hauke Wilcken (ORCID: https://orcid.org/0009-0009-6628-2278)
- Kristina Maas-Bauer
- Maren Hackenberg
- Justus Duyster
- Robert Zeiser
Institutions
- University of Freiburg (DE)
- University Medical Center Freiburg (DE)
- Collaborative Group (United States) (US)
- Alcoa (Germany) (DE)
- Offenburg University of Applied Sciences (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-19
- DOI
- https://doi.org/10.3389/fimmu.2025.1745873
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- Albert-Ludwigs-Universität Freiburg